Opinion|Videos|October 2, 2024
Evaluating Quality of Life and Adherence With mCRC Treatment Options
Medical experts discuss the impact of third-line therapies (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on patient quality of life and share insights on patient adherence to these treatments.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- What has been your experience with the impact of these third-line therapy options (regorafenib, fruquintinib, FTD/TPI plus bevacizumab) on a patient’s quality of life?
- What insights can you share related to patient adherence with third-line therapies in metastatic colorectal cancer?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
PBM Reforms Signed Into Law, Reshaping Medicare Part D Drug Pricing Transparency
2
Telomere Length and Polygenic Risk Shape Endotypes in Idiopathic Pulmonary Fibrosis
3
From Biologics to Bio-Machines: Top Takeaways From Maui Derm 2026
4
The Orphan Drug Act in the Modern Drug Pricing Era
5
